- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Tags
climate change One-on-One's biotech industry Industry Analysis patent biotechnology Benefits of biotech crops global food crisis agriculture biofuels Plant biotechnology Technology Transfer Biofuel Technology Food biofuel Sustainability Partnering BIO International Convention Health Care Biotechnology IndustryAuthors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas, CFA
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Tracy Cooley
Author Archive: Roy Zwahlen
Roy is a Manager of Intellectual Property and Technology Transfer policy at BIO and the main contributor for Patently BIOtech. He is a lawyer by training, with a background in international and national politics. He grew up in the developing world and believes that innovation can and does solve many of the world’s problems. Because of this, his work focuses on creating a worldwide policy environment that fosters innovation in the biotechnology sector to prevent and cure diseases such as HIV, to increase crop yields to feed more people, and to decrease the harmful effects of industry on the environment. Roy spends his free time keeping up with his two kids, a wife that knows everything (no joke), and serving in his church and broader community. Learn more about Roy from his Linkedin Profile.
Latest Posts
USTR: TPP to have High IP Standards to “Stand Alongside other Treaty Agreements in the Area”
Stan McCoy, Assisant U.S. Trade Representative for Intellectual Property and Innovation, spoke at BIO’s 2011 Convention session titled The Trans-Pacific Partnership and the Importance of Intellectual Property Rights: Attracting Investment in Biotechnology. The session covered the ongoing treaty negotiations and the relevance of different IP provisions to the biotechnology industry. Issues of particular importance to the biotechnology industry yet to be revelead to the public include language tabled for data protection and patent linkage. While USTR specific language is not available, Read More >
Patents in the U.S. Supreme Court
A special session at the 2011 BIO International Convention takes a fascinating look at the underlying factors involved in the U.S. Supreme Court hearing patent cases. The Supreme Court has been accepting patent cases at a higher rate than ever before, with three major patent appeals reviewed this past term alone. And the Court seems poised to accept several more in the coming year. According to the session moderator, Chief Judge (Ret.) Paul Michel from Read More >
Counterfeiting: White House IP Czar Victoria Espinel on working with corporations
White house IP Czar Victoria Espinel spoke at BIO’s 2011 International Convention in a session titled Counterfeiting: How corporations and government can work together. She told the audience that when entering her new assignment she was surprised to find out that counterfeiting was a large problem in the United States and not just abroad. The Administration has increased enforcement in counterfeit medicines as seizures of health related counterfeits have gone up 97% from last year. Read More >
Biotech Patenting and Tech Transfer at 2011 BIO International Convention
The Biotech Patenting and Tech Transfer track has a lot to offer 2011 BIO International Convention Attendees. High level speakers include White House Intellectual Property Enforcement Coordinator Victoria Espinel, European Patent Office Director of Biotechnology Sjoerd Hoekstra, retired Chief Judge of the U.S. Court of Appeals for the Federal Circuit Paul Michel, and former Solicitors General Seth Waxman and Paul Clement to name a few. I am particularly excited about the breadth of the Read More >
Patently BIOtech
Leave a comment
Email This Post
Tags: 2011 BIO International Convention, BIO, biosimilars, Biotech Patenting, collaboration, Collaborative R&D, Compulsory Licensing, Counterfeiting, EPO, Myriad Case, Patent Linkage, Patents in the Supreme Court, Paul Clement, Paul Michel, Seth Waxman, Sjoerd Hoekstra, Tech Transfer, Technology Transfer, Victoria Espinel
Tags: 2011 BIO International Convention, BIO, biosimilars, Biotech Patenting, collaboration, Collaborative R&D, Compulsory Licensing, Counterfeiting, EPO, Myriad Case, Patent Linkage, Patents in the Supreme Court, Paul Clement, Paul Michel, Seth Waxman, Sjoerd Hoekstra, Tech Transfer, Technology Transfer, Victoria Espinel
House Patent Reform Bill, HR 1249, still has the Administration’s and BIO’s support
The White House, Office of Management and Budget, Office of Science and Technology Policy, and the United States Patent and Trademark Office have come out in support of HR 1249 and the Manager’s Amendment to the bill. The only caveat mentioned is that “final legislative action [should] ensure that the US Patent and Trademark Office’s (USPTO’s) fee collections are made fully available to support the nation’s patent and trademark system.” BIO also has come out in Read More >
